The appropriate dose of angiotensin‐converting‐enzyme inhibitors or angiotensin receptor blockers in patients with dilated cardiomyopathy. The higher, the better?

By  

ESC HEART FAILURE, Vol. 2, Iss. 4, 2015-12 ,pp. : 103-105

John Wiley & Sons Inc

Access to resources Recommend Favorite

Nationwide trends in the prescription of beta-blockers and angiotensin-converting enzyme inhibitors after myocardial infarction in Denmark, 1995–2002

By Gislason Gunnar   Abildstrom Steen   Rasmussen Jeppe   Rasmussen Søren   Buch Pernille   Gustafsson Ida   Friberg Jens   Gadsbøll Niels   Køber Lars   Stender Steen   Madsen Mette   Torp-Pedersen Christian  

Scandinavian Cardiovascular Journal, Vol. 39, Iss. 1-2, 2005-04 ,pp. : 42-49

Informa Healthcare

Access to resources Recommend Favorite

Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases

By  

Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Cardiovascular & Hematological Agents), Vol. 4, Iss. 1, 2006-01 ,pp. : 67-73

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of Effects of Low Dose of Spironolactone and a Thiazide Diuretic in Patients with Hypertension Treated with an Angiotensin-Converting Enzyme Inhibitor or an Angiotensin Type 1 Receptor Blocker

By Yutaka Miyashita   Mifune Mizuo   Kubota Eiji   Itoh Hiroshi   Saito Ikuo  

Clinical and Experimental Hypertension, Vol. 31, Iss. 8, 2009-12 ,pp. : 648-656

Informa Healthcare

Access to resources Recommend Favorite

Selective Peroxisome Proliferator-Activated Receptor-γ Modulation in the Treatment of Hypertension and Metabolic Syndrome: The Role of Angiotensin II Receptor Blockers

By Borghi Claudio  

High Blood Pressure & Cardiovascular Prevention, Vol. 13, Iss. 3, 2006-01 ,pp. : 81-84

Adis International

Access to resources Recommend Favorite